ArticleAnnals of clinical and translational neurology2022
Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE
Article in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review.Journal of Alzheimer's disease : JAD · 2024Pooled it
- Cerebrospinal Fluid Biomarker Ratio Concordance with Amyloid Positron-Emission Tomography: A Diagnostic Test Accuracy Meta-analysis.Neurology and therapy · 2026Article
- ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab.The journal of prevention of Alzheimer's disease · 2026Article
- Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.The journal of prevention of Alzheimer's disease · 2026Observational
- Prospective study on clinical utility of plasma p-Tau217 and other biomarkers in Japanese memory clinics using the LUMIPULSE platform.Alzheimer's research & therapy · 2026Observational
- Shunt surgery and lecanemab therapy in patients with idiopathic normal pressure hydrocephalus and alzheimer's disease: a report of two cases.Acta neurochirurgica · 2026Article
- Fully Automated Measurement of GFAP in CSF Using the LUMIPULSEInternational journal of molecular sciences · 2025Article
- Brain activation in older adults during odor identification is related to ApoE, t-tau/AβNeurobiology of aging · 2025Article
- Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Limited utility of imaging-based (N) markers in predicting cerebral spinal fluid Alzheimer's disease biomarker positivity in lecanemab-eligible mild cognitive impairment.Frontiers in neurology · 2025Article
- Alzheimer's Disease-Related Analytes Amyloid-β and Tau in Perilymph: Correlation With Patient Age and Cognitive Score.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024Article
- Glial Fibrillary Acidic Protein's Usefulness as an Astrocyte Biomarker Using the Fully Automated LUMIPULSEDiagnostics (Basel, Switzerland) · 2024Article
- Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer's disease and other neurodegenerative diseases.Acta neuropathologica communications · 2024Article
- Baseline CSF tau and short-term clinical change during lecanemab therapy: A prospective real-world cohort study in Japan.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Clinical utility of LUMIPULSE plasma p-tau217 to identify amyloid positivity among candidates for amyloid-targeting treatments in a real-world cohort.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Clinical utility of CSF Aβ38 in Japanese research and clinical cohorts.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Interchangeability of CSF and PET to identify Alzheimer's disease pathology.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesCerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well-established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the relationship between CSF biomarkers, measured by a fully automated immunoassay platform, and brain β-amyloid (Aβ) deposition status confirmed by amyloid positron emission tomography (PET).
methodsOne hundred ninety-nine CSF samples from clinically diagnosed AD patients enrolled in a clinical study and who underwent amyloid PET were used for the measurement of CSF biomarkers Aβ 1-40 (Aβ40), Aβ 1-42 (Aβ42), total tau (t-Tau), and phosphorylated tau-181 (p-Tau181) using the LUMIPULSE system. These biomarkers and their combinations were compared to amyloid PET classification (negative or positive) using visual read assessments. Several combinations were also analyzed with a multivariable logistic regression model.
resultsAβ42, t-Tau, and p-Tau181, and the ratios of Aβ42 with other biomarkers had a good diagnostic agreement with amyloid PET imaging. The multivariable logistic regression analysis showed that amyloid PET status was associated with Aβ40 and Aβ42, but other factors, such as MMSE, sex, t-Tau, and p-Tau181, did not significantly add information to the model.
conclusionsCSF biomarkers measured with the LUMIPULSE system showed good agreement with amyloid PET imaging. The ratio of Aβ42 with the other analyzed biomarkers showed a higher correlation with amyloid PET than Aβ42 alone, suggesting that the combinations of biomarkers could be useful in the diagnostic assessment in clinical research and potentially in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.